Human Factor VII (Factor 7) Chromogenic AssaySense Activity Assay KitHuman Factor VII (Factor 7) Chromogenic AssaySense Activity Assay Kit
Move your mouse over image or click to enlarge

Human Factor VII (Factor 7) Chromogenic AssaySense Activity Assay Kit

This assay employs a quantitative chromogenic activity technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
CF1007 96 Well Plate £402.19

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssaySense Chromogenic Activity Kits
Samples Serum, Cell Culture
Species Human
Assay Format Chromogenic Activity Assay
Product Size 96 Well Plate
Range 12.5 - 200 mIU/ml
Plex Number 1
Storage Refer to component labels for details
Applications Assay
Entrez Gene 2155
Omim 613878
UniProt P08709
UniGene Hs.36989
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Koizume S et al. (2009) Hepatocyte Nuclear Factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res. 7(12): 1928-1936 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Krysiak R and Okopien B (2011) Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Intern Med J. 41(6):473-481 
* Momot AP et al. (2014) Allowable values of different parameters of hemostatic system in physiological pregnancy. Kazakhstan Association of Medical Laboratory Diagnostics 4(11):49-59 
* Momot A at al. (2015) Dynamics of indicators of the hemostasis system in women during pregnancy and after childbirth. Laboratory Service. 2: 3-11. 

" title="

* Koizume S et al. (2009) Hepatocyte Nuclear Factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res. 7(12): 1928-1936 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Krysiak R and Okopien B (2011) Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Intern Med J. 41(6):473-481 
* Momot AP et al. (2014) Allowable values of different parameters of hemostatic system in physiological pregnancy. Kazakhstan Association of Medical Laboratory Diagnostics 4(11):49-59 
* Momot A at al. (2015) Dynamics of indicators of the hemostasis system in women during pregnancy and after childbirth. Laboratory Service. 2: 3-11. 

" target="_blank">

* Koizume S et al. (2009) Hepatocyte Nuclear Factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res. 7(12): 1928-1936 
* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2 
* Krysiak R and Okopien B (2011) Haemostatic effects of simvastatin in subjects with impaired glucose tolerance. Intern Med J. 41(6):473-481 
* Momot AP et al. (2014) Allowable values of different parameters of hemostatic system in physiological pregnancy. Kazakhstan Association of Medical Laboratory Diagnostics 4(11):49-59 
* Momot A at al. (2015) Dynamics of indicators of the hemostasis system in women during pregnancy and after childbirth. Laboratory Service. 2: 3-11. 

Related Documents